Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976088 | 0.89 | DAO (0.59) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL9976047 | 0.83 | DAO (0.60) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL103357 | 0.82 | RAB9A (0.76) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL4700934 | 0.80 | APP (0.68) | NPC1RAB9ATDP1SMPD1APP | |
| SCHEMBL23628928 | 0.80 | NPC1 (0.57) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL9778350 | 0.80 | RAB9A (0.57) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL9976049 | 0.80 | NPC1 (0.57) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL9976048 | 0.78 | NPC1 (0.53) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL23217240 | 0.78 | NPC1 (0.56) | NPC1RAB9ACYP1A2CYP2C19RECQL | |
| SCHEMBL9778461 | 0.76 | NPC1 (0.54) | NPC1RAB9ACYP1A2CYP2C19RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | MECP2, DNMT1, DNMT3B | NPC1 2614/4885RAB9A 4038/4885CYP1A2 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.